» Articles » PMID: 19151784

Molecular Recognition of Acute Myeloid Leukemia Using Aptamers

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2009 Jan 20
PMID 19151784
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

Cell surface proteins can play important roles in cancer pathogenesis. Comprehensive understanding of the surface protein expression patterns of tumor cells and, consequently, the pathogenesis of tumor cells depends on molecular probes against these proteins. To be used effectively for tumor diagnosis, classification and therapy, such probes would be capable of specific binding to targeted tumor cells. Molecular aptamers, designer DNA-RNA probes, can address this challenge by recognizing proteins, peptides and other small molecules with high affinity and specificity. Through a process known as cell-based SELEX, we used live acute myeloid leukemia (AML) cells to select a group of DNA aptamers, which can recognize AML cells with dissociation constants (Kd's) in the nanomolar range. Interestingly, one aptamer (KH1C12) compared with two control cell lines (K562 and NB4) showed significant selectivity to the target AML cell line (HL60) and could recognize the target cells within a complex mixture of normal bone marrow aspirates. The other two aptamers KK1B10 and KK1D04 recognize targets associated with monocytic differentiation. Our studies show that the selected aptamers can be used as a molecular tool for further understanding surface protein expression patterns on tumor cells and thus providing a foundation for effective molecular analysis of leukemia and its subcategories.

Citing Articles

Cerium oxide nanoparticles-assisted aptasensor for chronic myeloid leukaemia detection.

Nur Y, Zein M, Irkham I, Gaffar S, Subroto T, Hartati Y ADMET DMPK. 2024; 12(4):623-635.

PMID: 39473627 PMC: 11517519. DOI: 10.5599/admet.2404.


AptaDiff: de novo design and optimization of aptamers based on diffusion models.

Wang Z, Liu Z, Zhang W, Li Y, Feng Y, Lv S Brief Bioinform. 2024; 25(6).

PMID: 39431516 PMC: 11491854. DOI: 10.1093/bib/bbae517.


Advancements in Chronic Myeloid Leukemia detection: Development and evaluation of a novel QCM aptasensor for use in clinical practice.

Domsicova M, Kurekova S, Babelova A, Jakic K, Oravcova I, Nemethova V Biochem Biophys Rep. 2024; 39:101816.

PMID: 39263318 PMC: 11387267. DOI: 10.1016/j.bbrep.2024.101816.


Assessing Aptamer-Analyte Binding Kinetics by Microfluidic Fluorescence Microscopy.

Wen K, Meng X, Wang C, Zhao J, Botros S, Lin Q Sens Actuators B Chem. 2024; 401.

PMID: 38558786 PMC: 10977918. DOI: 10.1016/j.snb.2023.135018.


Nucleic acid therapeutics as differentiation agents for myeloid leukemias.

Kovecses O, Mercier F, McKeague M Leukemia. 2024; 38(7):1441-1454.

PMID: 38424137 PMC: 11216999. DOI: 10.1038/s41375-024-02191-0.


References
1.
Collins S, Robertson K, Mueller L . Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol Cell Biol. 1990; 10(5):2154-63. PMC: 360563. DOI: 10.1128/mcb.10.5.2154-2163.1990. View

2.
Leupin N, Kuhn A, Hugli B, Grob T, Jaggi R, Tobler A . Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines. Br J Haematol. 2006; 135(4):520-3. PMC: 1654200. DOI: 10.1111/j.1365-2141.2006.06342.x. View

3.
Tang Z, Shangguan D, Wang K, Shi H, Sefah K, Mallikratchy P . Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem. 2007; 79(13):4900-7. DOI: 10.1021/ac070189y. View

4.
Shangguan D, Li Y, Tang Z, Cao Z, Chen H, Mallikaratchy P . Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A. 2006; 103(32):11838-43. PMC: 1567664. DOI: 10.1073/pnas.0602615103. View

5.
Boyd A, Metcalf D . Induction of differentiation in HL60 leukaemic cells: a cell cycle dependent all-or-none event. Leuk Res. 1984; 8(1):27-43. DOI: 10.1016/0145-2126(84)90029-8. View